BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
Go back to BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 65.42 +0.69 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.73 | 52 Week High | $108.96 | |||
| Open | $65.34 | 52 Week Low | $62.12 | |||
| Day High | $66.21 | P/E | N/A | |||
| Day Low | $65.32 | EPS | $-1.27 | |||
| Volume | 612,616 | |||||
